Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Not Yet Recruiting NCT07917143

A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide Versus Placebo in Children and Adolescents With Hypochondroplasia

Conditions: Hypochondroplasia

Sex: All

Ages: 2 Years – 17 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 81

Sponsor: Ascendis Pharma A/S

Summary

This trial is being conducted to evaluate the efficacy, safety and tolerability of treatment with navepegritide subcutaneous (SC) injections once weekly in children and adolescents with hypochondroplasia aged 2 to 17 years.

Eligibility Criteria

Inclusion Criteria: * 1\. Age 2 to \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07917143). StuddyBuddy aggregates publicly available trial information.